Arrowhead Pharmaceuticals delivered a profitable fiscal Q1 2026 driven by a significant increase in revenue, reflecting milestone and collaboration-related income, while maintaining substantial cash resources to support pipeline advancement.

Arrowhead Pharmaceuticals reported a net loss of $175.241 million for the fiscal third quarter of 2025, with revenue of $27.767 million. The company maintained a strong balance sheet with total cash resources of $900.372 million and advanced several key pipeline candidates, including plozasiran, zodasiran, and ARO-ALK7, into late-stage or early-stage clinical trials.

Arrowhead Pharmaceuticals posted strong financial results for Q2 FY2025, driven by a major collaboration deal with Sarepta Therapeutics. The company reported significant revenue and net income, reinforcing its financial position ahead of anticipated product launches.

Arrowhead Pharmaceuticals reported a net loss of $173.085 million for the fiscal first quarter ended December 31, 2024, with total revenue of $2.5 million. The company emphasized its strategic achievements, including a major licensing deal with Sarepta Therapeutics worth up to $10 billion in potential milestones and the FDA's acceptance of its plozasiran NDA, positioning it for future growth and potential commercial launches.

Arrowhead Pharmaceuticals reported its fiscal year-end results, highlighted by the submission of an NDA for plozasiran and a significant licensing and collaboration agreement with Sarepta Therapeutics. These strategic moves aim to strengthen the company's balance sheet and advance its pipeline.

Arrowhead Pharmaceuticals reported its fiscal year 2024 third quarter results, featuring significant clinical progress with presentations and publications. The company also strengthened its balance sheet through a strategic financing agreement and a milestone payment, focusing on advancing plozasiran towards potential commercialization in 2025.

Arrowhead Pharmaceuticals reported a net loss of $125.3 million, or $1.02 per share, for the second quarter of fiscal year 2024. The company's revenue was $0, compared to $146.3 million in the same quarter last year. They received a $50 million milestone payment from Royalty Pharma plc in the third quarter of fiscal 2024.

Arrowhead Pharmaceuticals reported a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $132.864 million, or $1.24 per share, on revenue of $3.551 million for the fiscal 2024 first quarter ended December 31, 2023.

Arrowhead Pharmaceuticals announced its financial results for the fiscal year ended September 30, 2023. The company highlighted recent presentations of Phase 2 clinical data and the completion of toxicology studies for pulmonary candidates.

Arrowhead Pharmaceuticals reported a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $102.946 million, or $0.96 per share, for the fiscal third quarter ended June 30, 2023. Revenue for the quarter was $15.825 million.

Arrowhead Pharmaceuticals reported a net income attributable to Arrowhead Pharmaceuticals, Inc. of $48.675 million, or $0.45 per diluted share, for the fiscal second quarter ended March 31, 2023. The company earned milestone payments from Takeda and GSK.

Arrowhead Pharmaceuticals reported its fiscal year results, highlighting revenue and operating expenses. The company strengthened its balance sheet with the sale of Arrowhead’s royalty interest in olpasiran to Royalty Pharma.

Arrowhead Pharmaceuticals reported a net loss of $72.05 million, or $0.68 per share, for the fiscal third quarter ended June 30, 2022. Revenue was $32.41 million.

Arrowhead Pharmaceuticals reported a net income of $44.366 million and revenue of $151.805 million for the fiscal second quarter ended March 31, 2022.

Arrowhead Pharmaceuticals reported its fiscal year 2022 first quarter results with a revenue of $27.439 million and a net loss of $62.872 million, resulting in a net loss per share of $0.60.

Arrowhead Pharmaceuticals reported its fiscal year end results, with a net loss of $140.85 million, or $1.36 per share.

Arrowhead Pharmaceuticals reported revenue of $45.891 million and a net loss of $29.924 million for the fiscal third quarter ended June 30, 2021.

Arrowhead Pharmaceuticals announced its fiscal second quarter results with revenue of $32.811 million and a net loss of $26.818 million, resulting in a loss per share of $0.26.

Arrowhead Pharmaceuticals reported a decrease in revenue and a net loss for the first quarter of fiscal year 2021. The company is focused on developing RNAi therapeutics.

Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2020. The company earned two $20 million milestone payments from Amgen and signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT.

Arrowhead Pharmaceuticals reported revenue of $27.38 million and a net loss of $13.61 million for the third quarter of fiscal year 2020.

Arrowhead Pharmaceuticals reported a revenue of $23,528,853 and a net loss of $19,835,570 for the fiscal second quarter ended March 31, 2020.

Arrowhead Pharmaceuticals reported a net loss of $2.67 million, or $0.03 per share, and revenue of $29.45 million for the fiscal first quarter ended December 31, 2019.